期刊
RADIOTHERAPY AND ONCOLOGY
卷 154, 期 -, 页码 299-305出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2020.11.010
关键词
Bone metastases; Fractionation; Radiation therapy; Variation
资金
- Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) Translational Research Fellowship
- Cancer Institute NSW
The study found that single-fraction radiation therapy (SFRT) is underused for the treatment of bone metastases in New South Wales, Australia, with a higher 30-day mortality rate compared to multi-fraction radiation therapy (MFRT). Older patients, those with lower socioeconomic status, residing in outer regional areas, or with multiple comorbidities were more likely to receive SFRT. This indicates a need to increase the utilization of SFRT for bone metastases treatment.
Background and purpose: Adoption of single-fraction radiation therapy (SFRT) has not been universal in the palliative treatment of bone metastases, despite evidence supporting its safety and efficacy. The aim of this study was to assess SFRT use for bone metastases in New South Wales (NSW), Australia, and the rate of 30-day mortality (30DM). Materials and methods: This is a population-based cohort of patients who received palliative radiation therapy (RT) for bone metastases (2009-2014), as captured in the NSW Central Cancer Registry. A logistic regression model was used to identify factors associated with fractionation type. The proportion of patients dying within 30-days from treatment start date was calculated. Results: Of the 14,602 courses of palliative RT delivered for bone metastases, 30% were SFRT. SFRT was more likely to be delivered to older patients: >= 80 years (34%) versus < 60 years (28%). Patients with lower socioeconomic status (SES) (35%) were more likely to receive SFRT compared with higher SES (25%). SFRT delivered to patients from outer regional area of residence (34%) were higher compared to those from the major city (29%). The proportion of SFRT delivered to patients with comorbidities >= 2 (34%) was higher than patients with no comorbidity (29%). SFRT was associated with higher 30DM of 21% compared with 11% for multi-fraction RT (MFRT). Conclusion: SFRT is underused for the treatment of bone metastases in NSW. This is an impetus to develop tools making SFRT obligatory in this setting unless there is good justification not to. Crown Copyright (C) 2020 Published by Elsevier B.V.All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据